Superdrol Injectable (Methasterone)
An injectable oil suspension of methasterone (methyldrostanolone, 'Superdrol'), a highly potent 17-alpha-alkylated DHT-derived steroid usually taken orally. Injecting the unesterified compound does not remove its 17-alpha-alkyl group, so it remains strongly hepatotoxic while delivering large, dry strength and mass gains. It is a harsh compound with minimal formal human study, favoured for short, aggressive cycles.
01 Overview
Methasterone is a methylated derivative of drostanolone and one of the most potent oral anabolics per milligram. It does not aromatise, giving dry, hard gains, but it is heavily hepatotoxic and blunts lipids severely. Injectable versions circulate in the underground market, sometimes as micronised suspensions or dissolved in oil, on the premise of reducing gut exposure.
Route of administration does not change the fundamental problem: the 17-alpha-alkyl group that makes methasterone survive first-pass metabolism also causes liver strain regardless of how it enters the body. Injectable methasterone is therefore best regarded as an unstudied, harsh compound carrying oral-type toxicity plus injection risks.
02 Mechanism
Methasterone is a potent non-aromatising androgen receptor agonist; its 17-alpha-alkylation confers metabolic resistance and hepatotoxicity that persist by injection.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 70–140 mg/wk | IM | Roughly 10-20 mg/day equivalents; very potent per mg. |
| High (harsh) | 140–210 mg/wk | IM | Side effects escalate steeply; short cycles only. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Rapid dry strength and mass gainsHighly potent per milligram with no water retention. | Fast, dry gains | Anecdotal | |
| No estrogenic bloatDoes not convert to estrogen, giving a hard look. | Non-aromatising | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Lethargy and malaiseUsers commonly report fatigue and general unwellness on methasterone. | Moderate | Common | Anecdotal | |
| Severe hepatotoxicityMarked liver enzyme rises and case reports of cholestatic injury. | Severe | Common at cycle doses | Observational | |
| Severe lipid deteriorationDramatic drop in HDL and rise in LDL. | Severe | Very common | Observational |